Deep search
Profile Picture
  • Web
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent

News

Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers

The Motley Fool on MSN · 4h
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's goal to lead the weight loss market.
CBS News on MSN · 21h
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.
Insider on MSN · 10h
Hims & Hers stock plunges after Novo Nordisk ends its brief partnership
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its blockbuster drug Wegovy.
Pharmaceutical Technology
3h
Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug
Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...
1h
Hims & Hers Health: Significant Impact Of Partnership Termination With Novo Nordisk; Initiate With 'Sell'
Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC ...
18h
Novo Nordisk
Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing" Novo Nordisk said it will stop selling Wegovy on ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy